Denali therapeutics inc - provides broad update on its ripk1 program partnered with sanofi

Denali therapeutics inc - provides broad update on its ripk1 program partnered with sanofi.denali therapeutics inc - denali and sanofi pause dnl747 clinical activities.denali therapeutics inc - co, sanofi intend to accelerate dnl788 for development in neurological indications.denali therapeutics inc - safety endpoints were met in phase 1b patient studies with dnl747 in als and alzheimer's disease.denali therapeutics - to pause dnl747 clinical activities based on totality of dnl747 data, superior profile of backup compound dnl788.
DNLI Ratings Summary
DNLI Quant Ranking